Use of a Fermented Dairy Beverage in Cervical Cancer Patients Undergoing Concurrent Chemoradiation Therapy
Phase II Randomized, Double Blind Study of Probiotics in Patients With Cervical Cancer in Clinical Stages IIB Undergoing Concurrent Chemotherapy and Radiation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Globally, many cancer survivors have undergone radiotherapy (RT) to pelvic tumors, this confers an increased risk of intestinal damage, affecting the quality of life of patients. The role of intestinal microbiota on the development of gastrointestinal toxicity and radiation enteritis has been described in cervical cancer patients that received pelvic RT. In this project we investigated the effect that a fermented dairy beverage (Yakult) may have in the modulation of inflammation and consequently of gastrointestinal toxicity in locally advanced cervical cancer (LACC) patients treated with concomitant chemo-radiotherapy (CRT).
In Mexico, the incidence of cervical cancer is 23 cases in 100,000 women (2015, Secretaría de Salud). In the Mexican National Cancer Institute (Instituto Nacional de Cancerología; INCan), 80% of patients arrive at locally advanced stages (IB2-IVA), the standard treatment is based on CRT. Gastrointestinal symptoms experienced by patients that receive pelvic RT define the pelvic radiation disease (PRD). Acute PRD is the result of cell death in the crypt epithelium and an acute inflammatory response in the lamina propria, which results in an insufficient replacement of the villi, rupture and inflammation of the mucosal barrier. Symptoms develop in 60-80% of patients. These include nausea, diarrhea, tenesmus, abdominal pain, urgency, anorexia, bleeding and fatigue; these are dose-limiting symptoms and affect the patients' quality of life.
A recent study analyzed the microbiota of LACC patients and found that patients that develop PRD during treatment with CRT possess a different microbiota to those patients that do not develop severe gastrointestinal toxicity. Evidence points to the critical role that the microbiota and intestinal inflammation play for the development of PRD in LACC patients. Therefore, an optimal intervention that modulates the microbiota is essential. We aimed to investigate the effect that a dairy beverage fermented with the probiotic Lactobacillus casei Shirota may have on intestinal and systemic inflammation, and consequently gastrointestinal symptoms and quality of life in women with LACC, undergoing CRT.
METHODS. This study was a double blind, placebo-controlled trial for Stage IIB cervical cancer patients that underwent CRT. The intervention group consumed of 3 servings of the fermented dairy beverage (Yakult) a day. The control group consumed 3 servings of the placebo beverage (with the same organoleptic qualities of Yakult). Clinical toxicity was analyzed with the Common Toxicity Criteria Version 2. Quality of Life score was measured with the QLQC 30 EORTC questionnaire. Fecal calprotectin was quantified to determine intestinal inflammation. Pro- and anti-inflammatory cytokines were quantified in blood samples to determine systemic inflammation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tlalpan
-
Mexico City, Tlalpan, Mexico, 14080
- National Cancer Institute of Mexico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological confirmation of cervical cancer staged as IIB.
- Histology: Epidermoid, adenosquamous, and adenocarcinoma
- Without previous treatment
- Measurable disease
- Age between 18 and 70 years
- Functional status of 0-2 (WHO criteria)
- Normal hematological, renal and hepatic function
- Standard chest X-ray
- Informed consent
Exclusion Criteria:
- Patients with small cell carcinoma or other rare histologies (sarcomas, lymphomas)
- Patients with other clinical stages
- Patients with paraaotic nodes less than or equal to 1 cm.
- Patients with non-measurable disease
- Infections or serious diseases that prevent the use of chemotherapy
- Concomitant treatment with another experimental drug
- Pregnancy or lactation
- Mental diseases
- Patients with previously documented hypersensitivity reactions to lactobacilli.
- Diabetic patients or hyperglycemia higher than 145 mg/dL.
- Previous or concomitant malignancy except non-melanoma skin carcinoma
- Social, family or geographical conditions that suggest a poor adherence to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Fermented dairy beverage
Concumption of 3 servings of the fermented dairy beverage a day, during oncological treatment.
|
Placebo dairy beverage (placebo) is a sweetened dairy beverage.
Other Names:
|
|
Placebo Comparator: Placebo
Consumption of 3 servings of the placebo dairy beverage a day, during oncological treatment.
|
Placebo dairy beverage (placebo) is a sweetened dairy beverage.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical toxicity
Time Frame: Change from baseline up to 3 months after treatment finished
|
Toxicity was analyzed with the Common Toxicity Criteria Version 2. A grading (severity) scale is provided for each adverse event (AE) term. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. |
Change from baseline up to 3 months after treatment finished
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health Related Quality of Life
Time Frame: Change from baseline up to 3 months after treatment finished
|
It was measured with the EORTC QLQ-C30 V2.
|
Change from baseline up to 3 months after treatment finished
|
|
Pro- and anti-inflammatory cytokines
Time Frame: Change from baseline up to 3 months after treatment finished
|
Th1, Th2, Th17 and IL-10 citokines were quantified in blood samples to determine systemic inflammation using immune assay ELISA.
|
Change from baseline up to 3 months after treatment finished
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lucely Cetina Pérez, MD, PhD, Instituto Nacional de Cancerologia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 008/043/ICI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.